Finally, Valeant had some decent news and the stock is going off like a rocket

Valeant Pharmaceuticals has announced that its internal Ad-Hoc committee of board of directors — put together to dig through the troubled company’s accounting — has completed its work.

The ad-hoc committee says that it found no more issues with the company’s accounting beyond the $58 million misstatement that has forced it to delay its annual report.

The stock is up 17% in Tuesday’s pre-market trading session.

NOW WATCH: James Altucher makes an argument for not paying back your credit card debt

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.